Study for effects of rosuvastatin on glucose and lipid metabolism in patients with type 2 diabeteic patients

Study for effects of rosuvastatin on glucose and lipid metabolism in patients with type 2 diabeteic patients - Effects of rosuvastatin on glucose and lipid metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009156

Enrollment

Registered

2012-10-20

Start date

2012-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabeteic patients with dyslipidemia

Interventions

Rosuvastatin 5mg/day (Patients under other statins are switched to rosuvastatin at the dose of 5 mg/day.)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes 2)Patients with other statins for more 2 months 3)LDL-C >= 100 mg/dl

Exclusion criteria

Exclusion criteria: 1)HbA1c>=9.4 %(NGSP) 2)Patients with type 1 diabetes,Severe ketosis,Diabetic coma 3)Patients with hyperkalemia 4)Patients with severe liver failure or renal failure 5)Patient with severe infection, perioperative,severe trauma 6)Pregnant and possibly pregnant women 7)Patients having liver failure,and getting a rash for statins 8)Other patients determined to be inappropriate by physician

Design outcomes

Primary

Measure	Time frame
Changes of HbA1c, nonHDL-C, T-C, LDL-C, HDL-C from the baseline to 6 months later.	—

Secondary

Measure	Time frame
Change of C-peptide, sd-LDL, MDA-LDL, Apo-B, Apo-AI, Cystatin C,high-molecular-weight adoponectin, TNF-alpha from the baseline to 6 months later.	—

Countries

Japan

Contacts

Public ContactAkiko Kameda

Yokohama City Unuversity School of Medicine Department of Endcrinology & Metabolism

t126022b@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026